## 🔬 Default Research Prompt Template

Use this template to invoke PharmaScope's full analytical capabilities. Copy and customize the bracketed sections.

---

**Research Request:**

I need a comprehensive pharmaceutical research analysis on **[DRUG NAME / TARGET / THERAPEUTIC AREA / RESEARCH QUESTION]**.

**Context & Objective:**
- **Program stage**: [e.g., target validation / lead optimization / Phase II clinical / competitive assessment]
- **My role**: [e.g., medicinal chemist / clinical scientist / BD & licensing / medical affairs]
- **Decision needed**: [e.g., go/no-go on target / compare pipeline assets / design next experiment / regulatory strategy]

**Specific Questions:**
1. [Primary question — e.g., What is the current clinical evidence for efficacy and safety?]
2. [Secondary question — e.g., How does this asset compare to [COMPETITOR DRUG]?]
3. [Tertiary question — e.g., What are the key development risks and mitigation strategies?]

**Scope Preferences:**
- **Depth**: [Quick briefing / Standard analysis / Deep dive with tables]
- **Focus areas**: [Mechanism / Clinical data / Regulatory / Competitive / Safety / PK-PD]
- **Time horizon**: [Current landscape only / Include pipeline catalysts through 2027]

**Available Data (optional):**
[Paste any proprietary summaries, conference abstracts, or internal data points here]

---

### Quick-Start Variants

**Literature Synthesis:**
> "Synthesize the current evidence on [TARGET/MOA] in [DISEASE]. Include genetic validation, key preclinical studies, and active clinical programs. Rate evidence strength and identify the most promising therapeutic approach."

**Competitive Landscape:**
> "Map the competitive landscape for [THERAPEUTIC AREA/INDICATION]. List all assets by development stage, MOA, latest clinical data, and differentiation. Highlight white space opportunities."

**Trial Design Critique:**
> "Critically evaluate the Phase [X] trial design for [DRUG] (NCT[NUMBER] if known). Assess endpoints, population selection, statistical powering, and potential biases. Suggest improvements."

**Regulatory Strategy:**
> "Outline the regulatory pathway for [DRUG/MODALITY] in [INDICATION] under FDA and EMA. Identify applicable expedited programs, key preclinical/clinical requirements, and likely review timeline."

**Safety Assessment:**
> "Provide a comprehensive safety profile analysis for [DRUG]. Cover mechanism-based toxicities, clinical AE profile, drug interactions, and special population considerations. Flag any black box warnings or REMS."